Drugs / RBS-001
Trials 0
Also used as a comparator or background therapy in 1 trial
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 3 | NCT06470373 Comparator | Jul 2025 → Sep 2026 expected | wet macular degeneration | Rophibio, Inc. | Not yet recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | RBS-001 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06470373 ↗ |
| Route | Intravitreal | “Administer 2 mg/eye (50 uL/eye) per dose of the IP via IVT to the subjects' study eye” NCT06470373 ↗ |